

JPFA 1632

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

7

Application Number

09/986,234

Filing Date

October 22, 2001

First Named Inventor

M. Lazar

Art Unit

1632

Examiner Name

A. Falk

Attorney Docket Number

UPN-L2066AUSA

### ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	31 Reference documents
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks

Customer No. 00270

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

HOWSON AND HOWSON

Signature

*Mary E. Bak*

Printed name

Mary E. Bak

Date

*July 19, 2005*

Reg. No.

31,215

### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

*Kelly A. Karstaedt*

Typed or printed name

Kelly A. Karstaedt

Date

*July 19, 2005*

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UPN-L2066AUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : 09/986,234

Confirmation No.: 4995

Applicant : M. Lazar

Filed : October 22, 2001

TC/A.U. : 1632

Examiner : A. Falk

Customer No. : 00270

Title : COMPOSITIONS, METHODS, AND KITS RELATING TO RESISTIN

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicants submit to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B is attached and copies of the documents are enclosed herewith. This Information Disclosure Statement is submitted more than three months from the filing date of this application but before the receipt of a first Office Action on the merits. Therefore, no fees are believed due.

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: July 19, 2005

Signature Kelly A. Karstaedt  
Name Kelly A. Karstaedt

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

#### REMARKS


The month of publication for documents BW, CT, CV, DW, DY, DZ, EV, and EW could not be determined. The years of publication for documents CT, DW, and DZ are sufficiently earlier than the effective US filing date and/or the foreign priority date of the present application so that the particular month of publication of the documents is not an issue (MPEP 609).

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON  
Attorneys for Applicants

By Mary E. Bak  
Mary E. Bak  
Registration No. 31,215  
Spring House Corporate Center  
Box 457  
Spring House, PA 19477  
Telephone: (215) 540-9200  
Telefacsimile: (215) 540-5818



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/986,234
				Filing Date	October 22, 2001
				First Named Inventor	M. Lazar
				Group Art Unit	1632
				Examiner Name	A. Falk
Sheet	1	of	4	Attorney Docket Number	UPN-L2066AUSA

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BL	WO-92/07065	04-30-1992	Eckstein et al.		

Examiner Signature		Date Considered	
--------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.

**SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/986,234
		Filing Date	October 22, 2001
		First Named Inventor	M. Lazar
		Group Art Unit	1632
		Examiner Name	A. Falk
Sheet 2 of 4	Attorney Docket Number		UPN-L2066AUSA

## NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	BV	BEVINS et al., "Defensins and innate host defence of the gastrointestinal tract", <i>Gut</i> <b>December 1999</b> 45(6):911-915	
	BW	BODMER, W., "Familial adenomatous polyposis (FAP) and its gene, APC", <i>Cytogenet. Cell Genet.</i> <b>1999</b> 86(2):99-104	
	BX	BUCKA-LASSEN et al., "Combining many multiple alignments in one improved alignment", <i>Bioinformatics</i> <b>February 1999</b> 15(2):122-130	
	BY	CHAWLA et al., "Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation", <i>Endocrinol.</i> <b>August 1994</b> 135(2):798-800	
	BZ	FRANZ-BACON et al., N_Geneseq_0601 Accession No. AAV84055, pp. 1-2, <b>December 1998</b>	
	CR	FRANZ-BACON et al., Geneseq Accession No. AAV84058, pp. 1-2, <b>December 1998</b>	
	CS	FRANZ-BACON et al., A_Geneseq_0601 Accession No. AAW87706, pp. 1-2, <b>December 1998</b>	
	CT	FREUNDLIEB et al., "Use of tetracycline-controlled gene expression systems to study mammalian cell cycle", <i>Methods Enzymol.</i> <b>1997</b> 283:159-173	
	CU	GHOSH et al., "Ulcerative colitis", <i>BMJ</i> <b>April 22, 2000</b> 320(7242):1119-1123	
	CV	GURNEY et al., Geneseq Accession No. AAZ34983, pp. 14-15, <b>1999</b>	
	CW	HAMMER et al., "Diagnostic criteria for the irritable bowel syndrome", <i>Am. J. Med.</i> <b>November 8, 1999</b> 107(5A):5S-11S	
	CX	HASELHOFF et al., "Simple RNA enzymes with new and highly specific endoribonuclease activities", <i>Nature</i> <b>August 18, 1988</b> 334(6183):585-591	
	CY	HOUDEBINE, LM, "Production of pharmaceutical proteins from transgenic animals", <i>J. Biotechnol.</i> <b>May 31, 1994</b> 34(3):269-287	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/986,234	
			Filing Date	October 22, 2001	
			First Named Inventor	M. Lazar	
			Group Art Unit	1632	
			Examiner Name	A. Falk	
Sheet	3	of	4	Attorney Docket Number	UPN-L2066AUSA

## NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	CZ	HUANG et al., "Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway", <i>Gene Dev.</i> <b>January 1, 2000</b> 14(1):45-54	
	DR	KAPPEL et al., "Regulating gene expression in transgenic animals", <i>Curr. Opin. Biotechnol.</i> <b>October 1992</b> 3(5):548-553	
	DS	KAYE et al., "A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding", <i>Proc. Natl. Acad. Sci. USA</i> <b>September 1990</b> 87(17):6922-6926	
	DT	MARRA et al., EST Accession No. AA518288, pp. 4, <b>July 1997</b>	
	DU	MARRA et al., EST Accession No. AA245583, pp. 9-10, <b>March 1997</b>	
	DV	MARKS et al., "By-passing immunization. Human antibodies from V-gene libraries displayed on phage", <i>J. Mol. Biol.</i> <b>December 5, 1991</b> 222(3):581-597	
	DW	NCI-CGAP Accession No. AA524300, pp. 2-3, <b>1997</b>	
	DX	OHGI et al., "Expression of RNase Rh from <i>Rhizopus niveus</i> in yeast and characterization of the secreted proteins", <i>J. Biochem.</i> <b>May 1991</b> 109(5):776-785	
	DY	PELTOMAKI et al., "The genetics of hereditary non-polyposis colorectal cancer and non-polypotic colon cancer", <i>Adv. Exp. Med. Biol.</i> <b>1999</b> 470:95-98	
	DZ	RUDINGER, Peptide Hormones, Parsons (Ed.), University Park Press, Baltimore, pp. 1-7 <b>1976</b>	
	ER	SCHRODER, J.M., "Epithelial antimicrobial peptides: innate local host response elements", <i>Cell Mol. Life Sci.</i> <b>October 1, 1999</b> 56(1-2):32-46	
	ES	SKOLNICK et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era", <i>Trends Biotechnol.</i> <b>January 2000</b> 18(1):34-39	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/986,234
		Filing Date	October 22, 2001
		First Named Inventor	M. Lazar
		Group Art Unit	1632
		Examiner Name	A. Falk
Sheet 4 of 4	Attorney Docket Number		UPN-L2066AUSA

## NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	ET	SU et al., "Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene", <i>Science</i> May 1, 1992 256(5057):668-670	
	EU	WEINTRAUB, H.M., "Antisense RNA and DNA", <i>Sci. Am.</i> January 1990 262(1):40-46	
	EV	WILLIAMS et al., "Asynchronous development of the rat colon", <i>Anat. Embryol.</i> 1991 183(6):573-578	
	EW	WRIGHT et al., "Genetically engineered antibodies: progress and prospects", <i>Crit. Rev. Immunol.</i> 1992 12(3-4):125-168	
	EX	YANG et al., "Intestinal inflammation reduces expression of DRA, a transporter responsible for congenital chloride diarrhea", <i>Am. J. Physiol.</i> December 1998 275 (6.1):G1445-1453	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.